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ICSBP (interferon consensus sequence binding protein)/IRF8 (interferon regulatory factor 8) is an interferon gamma-inducible transcription
factor expressed predominantly in hematopoietic cells, and down-regulation of this factor has been observed in chronic myelogenous leukemia
and acute myeloid leukemia in man. By screening about 1200 murine leukemia virus (MLV)-induced lymphomas, we found proviral insertions at
the Icsbp locus in 14 tumors, 13 of which were mature B-cell lymphomas or plasmacytomas. Only one was a T-cell lymphoma, although such
tumors constituted about half of the samples screened. This indicates that the Icsbp locus can play a specific role in the development of mature B-
lineage malignancies. Two proviral insertions in the last Icsbp exon were found to act by a poly(A)-insertion mechanism. The remaining insertions
were found within or outside Icsbp. Since our results showed expression of Icsbp RNA and protein in all end-stage tumor samples, a simple tumor
suppressor function of ICSBP is not likely. Interestingly, proviral insertions at Icsbp have not been reported from previous extensive screenings of
mature B-cell lymphomas induced by endogenous MLVs. We propose that ICSBP might be involved in an early modulation of an immune
response to exogenous MLVs that might also play a role in proliferation of the mature B-cell lymphomas.
© 2006 Elsevier Inc. All rights reserved.Keywords: Murine leukemia virus; Insertional mutagenesis; B-cell lymphomas; Plasmacytoma; Common integration siteIntroduction
Interferon (IFN) consensus sequence binding protein
(ICSBP), also known as interferon regulatory factor 8 (IRF8),
is a member of a family of transcription factors termed IFN
regulatory factors (IRFs) (Driggers et al., 1990; Taniguchi et al.,
2001). It is a 50 kDa protein first identified as an interferon γ
(IFNγ) inducible protein that binds to the promoter of the MHC
class 1 gene through the interferon consensus sequence (ICS).
Originally identified as a transcription repressor (Weisz et al.,
1992), ICSBP regulates transcription in the immune system
(Tamura and Ozato, 2002; Wang et al., 2000) through multiple
target DNA elements, including IFN-stimulated response⁎ Corresponding author. Fax: +45 8619 6500.
E-mail address: fsp@mb.au.dk (F.S. Pedersen).
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doi:10.1016/j.virol.2006.05.006element (ISRE) (Darnell et al., 1994; Harada et al., 1989;
Kessler et al., 1988; Tanaka et al., 1993), Ets/IRF composite
element EICE (Driggers et al., 1990; Eisenbeis et al., 1995;
Klemsz et al., 1990; Marecki et al., 2001; Rao et al., 1999), IFN-
gamma activation site (GAS) (Contursi et al., 2000; Darnell et
al., 1994), and hematopoiesis-associated factor-1(HAF1)-cis
element (Kakar et al., 2005). The DNA-binding motif of ICSBP
shares significant sequence similarities with other IRF family
members at the first 115 amino acids, which comprise the DNA-
binding domain (DBD) (Sharf et al., 1995). ICSBP exerts its
transcriptional activity through interaction with other IRF
members, by protein–protein interaction through the IRF
association domain (IAD) (Levi et al., 2002) that, except for
IRF1 and IRF2, shares sequence similarities among the IRF
members. In addition, ICSBP interacts with other transcription
factors, such as PU1, E47, and NFAT, through the PEST domain
(Bovolenta et al., 1994; Eklund and Kakar, 1999; Meraro et al.,
307S.L. Ma et al. / Virology 352 (2006) 306–3181999). The dual role of ICSBP is demonstrated by the fact that
interaction with IRF-1 or IRF-2 on ISRE leads to the formation
of a heterocomplex with repression activity, while on the
contrary, interactions with PU.1 and E47, or NFAT result in the
formation of transcriptional activation heterocomplexes (Rehli
et al., 2000; Schmidt et al., 2004; Zhu et al., 2003).
Among the IRFs, ICSBP is expressed exclusively in cells of
the immune system such as monocytes/macrophages, dendritic
cells, B-cells, and activated T-cells (Driggers et al., 1992; Lu et
al., 2003; Nelson et al., 1993; Schiavoni et al., 2002; Tsujimura
et al., 2002; Weisz et al., 1994; Weisz et al., 1992). A number
of studies have established an essential role for ICSBP in the
differentiation of myeloid progenitor cells toward mature
macrophages while blocking differentiation toward granulo-
cytes (Tamura et al., 2000; Tamura and Ozato, 2002), and it has
been shown that mice with Icsbp null mutation are defective in
this feature (Wang et al., 2000). In fact, several studies have
confirmed that ICSBP does play a role in regulating pathways
affecting myeloid lineage commitment (Nagamura-Inoue et al.,
2001), including a study in which lineage marker-negative
(Lin−) bone marrow progenitor cells were used to validate the
involvement of ICSBP in controlling myeloid lineage prolif-
eration. It was shown that an ICSBP-deficient mouse
developed granulocytic leukemia, a condition very similar to
human chronic myelogenous leukemia (CML) (Holtschke et
al., 1996). In line with this, low levels of Icsbp transcripts have
been observed in human acute myeloid leukemia (AML) and
CML patients, where the decreased transcript levels could be
reversed by treatment with IFN-α (Schmidt et al., 1998). In
other studies, a significantly decreased ICSBP expression level
was observed in BCR-ABL-induced CML disease, and by
using a mouse model, it was shown that forced co-expression
of ICSBP attenuated BCR-ABL induced CML (Hao and Ren,
2000). In contrast to a well-documented role in the myeloid
lineage, reports of the role of the Icsbp gene in B-cell or T-cell
development are quite sparse. Still, one study showed B-cell
development blockage in IRF4−/−, ICSBP−/− mice, without
impairing T-cell development in the thymus (Lu et al., 2003),
and very recently Lee et al. (2006) have shown by siRNA
knockdowns of ICSBP expression in a mouse B-cell
lymphoma cell line that activation-induced cytidine deaminase
(AID) and BCL6 might be important transcriptional targets of
ICSBP.
Retroviral insertional mutagenesis has been studied in
different mouse models (Hansen et al., 2000; Jonkers and
Berns, 1996; Martin-Hernandez et al., 2001), and with complete
mouse genome information available, proviral tagging has
become a powerful tool for the identification of cancer-related
genes (Kim et al., 2003; Mikkers et al., 2002a, 2002b; Suzuki et
al., 2002). In that respect and to broaden our understanding of
diseases in the hematopoietic system, we have used the inbred
NMRI mouse strain infected with the nonacutely transforming,
ecotropic murine leukemia viruses (MLVs), Akv and SL3-3
retroviruses, as prototypic models of B- and T-cell tumorigen-
esis, respectively.
By means of high-through-put screening procedures, we
here report of the finding of 14 MLV proviral insertions atthe Icsbp locus, 13 of which are from the B-lymphotropic
Akv (or derivates thereof)-induced lymphomas, while a
single one is from a diffuse large B-cell lymphoma
induced by an SL3-3 variant containing severe enhancer
mutations. Remarkably, we did not observe any hits in
SL3-3 MLV-induced T-cell lymphomas, which led us to
examine possible, specific functions of Icsbp expression in
MLV-induced B-cell lymphomas. Overall, our findings
strongly suggest a differential role of Icsbp in B-cell
lymphomagenesis as compared to T-cell lymphomagenesis.
However, as no major changes of Icsbp RNA or protein
expression levels in the end-stage tumor samples could be
observed, a straightforward oncogenic overexpression or
tumor suppressor function of Icsbp in B-cell tumors is
unlikely.
Results
The Icsbp locus is a frequent target in MLV-induced
lymphomas
Screening tumors from 1203 mice resulted in about 3000
retroviral tags. Of these, 14 integrations (from 14 different mice)
were found within a 100 kb region encompassing the Icsbp
locus, which is 140 times higher than the average frequency of
3000 integrations over the whole genome. The tagging-site
selection difference from randomness was supported statisti-
cally by applying the (χ2) test (P < 0001). This strongly
indicates that the Icsbp insertions have been selected for during
lymphomagenesis and hence that Icsbp can indeed play a role in
lymphoma development.
As seen in Fig. 1, the integration sites were evenly
distributed along the Icsbp locus without any orientation
preference. Nine integrations were found in the same, and 5
in the opposite transcriptional orientation as compared to that of
the target gene.
Icsbp integrations are specific for tumors of B-cell origin
Since about half of the investigated tumors resulted from
experimental series employing viruses belonging to the T-
lymphomagenic SL3-3 MLV type (Table 1), it is striking that all
but one of the Icsbp integrated proviruses were found in tumors
induced by the Akv MLV type, and moreover, the single one not
conforming to this type was found in a tumor induced by a
seriously weakened enhancer mutant of SL3-3. Mutants from
this series did not at all behave like the conventional SL3-3
MLV type, i.e. they did not induce T-cell lymphomas, and
indeed histopathology analyses of this particular tumor revealed
that it could be classified as a diffuse large B-cell lymphoma
(Table 2).
By morphological examination, all 14 mice in question
presented with enlargement of spleen and mesenteric lymph
nodes, and in two cases a slightly enlarged thymus was
observed as well. This is in contrast to what is usually
observed for SL3-3 MLV-infected mice, which in almost
100% of the cases display a significant thymus enlargement.
Fig. 1. The Icsbp locus and inserted proviruses. Upper panel: map of the Icsbp locus and flanking genes on mouse chromosome 8. The distance between Icsbp and
Cox4i1 is 37.832 bp, and between Icsbp and Foxf1a is 325.958 bp (UCSC assembly; mm6). Lower panel: exon–intron map of the Icsbp transcription unit with
indication of positions and transcriptional orientations of inserted proviruses in tumor DNAs marked by tumor IDs. A total of 14 proviral insertions within a 1 × 105 bp
window at the Icsbp locus are depicted, 5 upstream of, 6 within, and 3 downstream of the predicted Icsbp transcription unit. The triangles indicate the transcription
orientation of the proviruses. The nine Icsbp exons are marked as rectangles with the coding regions in black and the noncoding regions in white. Exon 9 harbors
coding sequences followed by a long 3′-untranslated region.
308 S.L. Ma et al. / Virology 352 (2006) 306–318Of the 14 Icsbp integrations, 12 were found in DNA from
enlarged spleens, while 2 were identified in DNA of
enlarged thymuses (99-190 and 98-1162).
Southern blotting analyses (summarized in Table 2) with
TCR-β probes did not, except in a single case (which also
revealed rearrangements of Igκ and IgH), show rearrange-
ments of the TCR-β gene in any of the examined tumor
samples (data not shown), indicating that the Icsbp-targeted
lymphomas are not in general of T-cell origin. This was
further supported by the observations of frequent rearrange-
ments of Igκ and/or IgH genes, when the same Southern
membranes were hybridized with probes recognizing these
genes (data not shown); accordingly, these results pointed to
a B-cell tumor phenotype of the Icsbp tumors. Finally,
hybridizations with Icsbp cDNA and ecotropic-specific
envelope probes did not reveal any clonal provirus
integrations (examples are provided in Fig. 2), which –
with respect to provirus integration – indicate tumors of a
polyclonal nature.Table 1
Distribution of Icsbp locus integrations among virus/host models
Model, virus type a/mouse strain b No. of mice tagged
(no. of mice with Icsbp integrations)
Akv/NMRI-i 524 (13)
Akv/SWR 37 (0)
SL3-3/NMRI-r 58 (1)
SL3-3/NMRI-i 327 (0)
SL3-3/SWR 98 (0)
Akv + SL3-3/NMRI-i 159 (0)
Total 1203 (14)
a Virus type indicates wild type as well as all derived mutants.
b NMRI-i denotes inbred NMRI; NMRI-r, randomly bred NMRI.Tumors with Icsbp insertions are mostly diffuse large B-cell
lymphomas and plasmacytomas
As summarized in Table 2, the hematopoietic neoplasms
observed in the lymphoid organs of 14 mice infected with
viruses with proviral insertion sites at the Icsbp locus could be
classified as plasmacytoma (PCT) (6/14; 43%), diffuse large B-
cell lymphoma (DLBCL) (6/14; 43%), or precursor T-cell
lymphoblastic lymphoma (pre-T LBL) (1/14; 7%). In only one
case (1/14; 7%; tumor 01-743), no histological evidence for a
neoplastic disease, but a reactive plasma cell proliferation was
found. In this case, a moderate proliferation of plasma cells and
hyperplastic reactive germinal centers were observed.
Peripheral lymph nodes and the spleen were enlarged in all
animals. In plasmacytomas, in addition to a severe plasma cell
proliferation, which destroyed the normal architecture of the
lymph nodes (Fig. 3G), hyperplastic germinal centers without a
mantle zone, so called “naked germinal centers”, were
observed. In the spleen, both the red and the white pulp were
affected, and also nonlymphoid organs, e.g. liver, were
massively infiltrated by neoplastic plasma cells (Fig. 3H).
Plasma cells were either medium-sized (Figs. 3G–I) with a
monotonous morphology or slightly pleomorphic with bigger,
irregular-shaped nuclei, and a blastic chromatin pattern (Figs.
3J–L). Plasma cells were CD79acy-positive and CD138-
positive or -negative. It should be noted that a remaining
normal hematopoiesis was still present in all mice.
The infiltration pattern of diffuse large B-cell lymphomas in
the spleen and lymph nodes was diffuse (Figs. 3D–F) and large
neoplastic B-cells were B220- and CD79acy-positive (not
shown) with abundant pale cytoplasm, big nuclei with open
chromatin, and one to three distinct nucleoli. Many mitotic
figures indicated a high proliferation rate, which was also
Table 2
Tumor panels of mice harboring integrations in the Icsbp locus
Tumor ID Virus variant a Mouse
strain
Lymphoma
incidence,
n/total
Mean
latency,
days (SD)
Specific
tumor
latency,
days
Tumor phenotype
DNA analysis b Histopathology c
Igκ IgH TCR Eco
01-282 Akv wt NMRI-i 16/16 178 (31) 181 + + + P DLBCL
98-1162 Akv wt NMRI-i 20/20 161 (36) 140 − − − P DLBCL
99-190 Akv PBS lys NMRI-i 20/20 206 (30) 225 − − − P DLBCL
01-241 Akv1-99 wt NMRI-i 18/19 179 (18) 175 + + − P DLBCL
01-325 Akv1-99 wt NMRI-i 16/16 179 (18) 173 − − − P PCT
00-258 Akv SA' gag mutant (CD) NMRI-i 17/20 209 (26) 245 ND ND ND ND PCT
01-994 Akv1-99 mEa/s NMRI-i 42/42 163 (23) 170 + − − P PCT
01-1080 Akv1-99 mEa/s NMRI-i 5/5 182 (9) 183 − − − P PCT
01-314 Akv1-99 (mEgre + mEa/s) NMRI-i 44/44 154 (44) 106 ND ND ND ND pre-T LBL
01-990 Akv1-99 (mEgre + mEa/s) NMRI-i 44/44 154 (44) 231 ND ND ND ND PCT
01-742 Akv1-99 (mRunx I + mEgre) NMRI-i 27/28 204 (27) 183 + − + P PCT
01-743 Akv1-99 (mRunx I + mEgre) NMRI-i 27/28 204 (27) 183 − − − P Plasma cell
proliferation
99-1260 Akv1-99 (dm NF1) NMRI-i 18/20 186 (26) 225 − + − P DLBCL
91-1536 SL3-3 Runx dm NMRI-r 1/19 NA 190 ND ND ND ND DLBCL
NA indicates not applicable; and ND, not determined.
a The viruses mentioned here originated from published work (Ethelberg et al., 1997, 1999; Hallberg et al., 1991; Lovmand et al., 1990, 1998; Lund et al., 1999;
Olsen et al., 1990; Sorensen et al., 2005) as well as unpublished pathogenicity studies.
b The tumor DNAwas analyzed by Southern blot hybridizations using probes detecting rearrangements in Igκ, IgH, or TCR (+ denotes rearrangement; − denotes
no rearrangement). An ecotropic specific probe (Eco) was used to detect clonally integrated proviruses; P denotes a polyclonal-like pattern, i.e. many weak (or no)
hybridizing fragments.
c Histological and immunohistological analyses were performed as described. DLBCL denotes diffuse large B-cell lymphoma; PCT, plasmacytoma; and pre-T
LBL, precursor T-cell lymphoblastic lymphoma.
309S.L. Ma et al. / Virology 352 (2006) 306–318demonstrated with anti Ki-67 immunohistochemistry (Fig. 3E),
and many reactive CD3-positive T-cells were present (Fig. 3F).
In addition, reactive eosinophilic granulocytes and histiocytes
were intermingled with the neoplastic cells.
One tumor was classified as a precursor T-cell lymphoblastic
lymphoma (Figs. 3A–C). Thymus, spleen, cervical, and
mesenteric lymph nodes were enlarged. At lower magnification,
a distinct starry sky pattern with many tingible bodies was
present, especially in the thymus.Monotonous, blastic, medium-
sized, CD3-, and TdT-positive tumor cells (Figs. 3B, C) showed
a high proliferation rate and were infiltrating lymphatic and
nonlymphatic tissues. This T-cell tumor developed with a
slightly shorter latency period (106 days) as compared to the
other tumors. In this exceptional case, both spleen, from which
the Icsbp integration was found, and thymus were analyzed, and
both tissues exposed the same phenotype. In spite of the single
exceptional case, which may or may not represent a random
integration (i.e. an integration not selected for during tumor
development), the overall picture remains that Icsbp insertions
are tightly associated with mature B-cell neoplasms.
No major effect of proviral insertions on Icsbp mRNA levels
In order to analyze a possible effect of the Icsbp integrated
proviruses on the Icsbp mRNA pattern in the MLV-induced
tumors, Northern blot analyses were performed for 10 of the 14
tumors, in which both a change in the amount of mRNA and a
change in transcript sizes were detected. Four different Icsbp
cDNA probes (depicted in Fig. 4), covering different parts of the
cDNA, were generated.In order to distinguish a change in mRNA pattern likely
to be caused by an integrated provirus, mRNA from tumors
from the same experimental series – but without an
integration in the Icsbp locus – served as controls. These
control tumors thus exemplify the typical Icsbp mRNA
pattern in an MLV-induced tumor. Examples of Northern blot
analyses of different experimental series are shown in Figs.
4, 5, and 6. These show that the general Icsbp expression
pattern in the MLV-induced tumors consists of two
transcripts of 3.0 kb and 1.7 kb, respectively, a pattern
which is in agreement with published results for the mouse
Icsbp gene (Driggers et al., 1990). Probe 537 (exon 2 to
exon 5) as well as probe 841 (exon 5 to exon 9) detected
both transcripts, whereas probe 909 (representing just exon
9) detected only the larger 3.0 kb transcript (Fig. 4). When
probe 47-1270 (covering all the coding sequences from exon
2 to 9) was used, again both transcripts were detected (Fig.
4), suggesting that the two transcripts share the same coding
sequence, and that the shorter transcript most likely is
generated by use of the alternative polyadenylation signal in
exon 9 (indicated in Fig. 4).
The two transcripts of 3.0 and 1.7 kb were seen in all cases
irrespective of the presence or absence of provirus integrations
into the Icsbp locus (Fig. 4), and, with the exception of the
formation of chimeric transcripts (Figs. 5 and 6, discussed later),
no major changes in expression levels were observed.
Accordingly, provirus insertion into the Icsbp locus does not
in general seem to affect the Icsbp mRNA pattern in MLV-
induced end-stage tumor tissues. This implies that neither a
straightforward overexpression of an oncogene nor an extinction
Fig. 2. Southern blot analyses of integrated proviruses. (A) Genomic DNAs from tumors harboring proviral integration in the Icsbp locus were isolated and digested
with NcoI and hybridized with an Icsbp cDNA probe covering the integration sites located in exon 9 (tumor 01-241 and 01-1080) (left panel; probe location shown in
panel B) or an ecotropic-specific MVLV probe (right panel; probe location shown in panel C). Lanes 1 and 2 are control DNAs from uninfected BALB/cJ and NMRI
mice. BALB/cJ contains one copy of an endogenous ecotropic MLV (serving as positive control for the Env probe), while NMRI contains no endogenous ecotropic
MLVs (serving as negative control for the Env probe). The l, t, and s (lymph node, thymus, and spleen, respectively) refer to the tumor tissues from which the DNAwas
isolated. (B) Location of the Icsbp cDNA probe 1096–1764. Numbers correspond to nucleotide positions in GenBank Accession Number M32489. The probe contains
23 bp of exon 8 and 643 bp of exon 9. Triangles below the map of the Icsbp locus illustrate (as in Fig. 1) positions and orientations of integrated proviruses with the
numbers referring to lane numbers in panel A. (C) Schematic illustration of the proviral DNA with location of Env probe and NcoI restriction sites indicated.
310 S.L. Ma et al. / Virology 352 (2006) 306–318of expression of a tumor-suppressor gene would provide an
explanation of the apparent oncogenic role of the proviral
integrations into Icsbp.
Chimeric Icsbp-retroviral transcripts in tumors
The two outstanding cases in the Northern-blot analyses
represented the only cases where the provirus integrations took
place inside the gene and within an exon. Tumors 01-1080 and
01-241 both harbored an integration in exon 9, the former in the
Icsbp coding region and the latter in the 3′ untranslated region
(Fig. 1). Besides, both proviruses were integrated in the same
transcriptional orientation as the Icsbp gene itself.
In the two exceptional cases, an altered expression pattern
was revealed as compared to that of the other tumor samples;
thus, in both instances, an additional, strongly expressed
transcript could be observed. Regarding tumor 01-241, the
size of the additional transcript was 2.1 kb (Fig. 5A); while in
the case of tumor 01-1080, the size was estimated to be about1.8 kb (Fig. 5B). The locations and orientations of the integrated
proviruses, taken together with the sizes of the alternative
transcripts observed by the Northern blotting hybridization,
suggested that chimeric transcripts consisting of Icsbp as well as
proviral sequences had been produced. In order to investigate
this, RT-PCRs were performed on tumor RNA, with the usage
of an Icsbp-specific upstream PCR primer together with a
provirus-specific downstream PCR primer (primer locations
depicted in Fig. 5). The results (shown in Fig. 5C) were
amplified fragments of the expected sizes of 1452 bp and
1696 bp, respectively. Subsequent determination of the
sequences confirmed the identity of the amplified fragments
and established that they were composed 5′ of truncated Icsbp
sequences and 3′ of proviral U3-R region, thus validating that
the poly(A) signal in the 5′LTR of the provirus had been used in
the production of the truncated Icsbp RNA.
In two additional tumor samples, a provirus was found
inserted in a co-transcriptional orientation within the gene (01-
742 and 01-282; Fig. 6), and hence a possibility for generating
Fig. 3. Histological and immunohistological analyses of lymphoid neoplasias in retrovirus-infected NMRI mice. (A–C) A mouse infected with Akv1-99
(mEgre + mEa/s) developed a precursor T-cell lymphoblastic lymphoma. The tumor is composed of monotonous population of medium-sized cells with blastic
chromatin. Arrows indicate areas of erythropoiesis. Neoplastic cells infiltrate the red and white pulp (A, H&E, spleen). The tumor cells are CD3-positive (B, thymus)
and TdT-positive (C, thymus). (D–F) Representative pictures of a diffuse large B-cell lymphoma. The tumor cells are large with irregular-shaped nuclei, open
chromatin, and abundant pale-stained cytoplasm (D, H&E, spleen). Ki-67 staining demonstrates a high proliferation rate in the neoplastic cells (E, spleen) that stained
positive for B220 (data not shown). Many reactive CD3-positive T-cells are present (F, spleen). The large neoplastic cells are negative for CD3 (arrows). (G–I) Severe
plasma cell proliferation is depicted. The infiltrate is present in the lymph nodes (G, H&E), liver (H, H&E), and spleen (I, H&E). In some cases, the plasma cells are
intermingled with large cells (arrows) or centroblasts (J, H&E), which have irregular-shaped nuclei with open chromatin. These centroblastic-appearing cells are
CD138-negative (K, arrows) and Ki-67-positive (L), suggesting progression of the disease.
311S.L. Ma et al. / Virology 352 (2006) 306–318chimeric transcripts was present also in these cases. However, in
contrast to tumors 01-1080 and 01-241, the integration sites
were located within an intron (intron 5 and intron 2,respectively). Again, RT-PCRs were performed with Icsbp-
specific upstream PCR primers together with a provirus-specific
downstream PCR primer (Figs. 6A, B), resulting in amplified
Fig. 4. Expression of long and short transcripts in tumors. Total RNA from 10 tumors induced byAkv1-99 dmNF1 and 10 tumors induced byAkv1-99 (mEgre +mEa/s)
was analyzed by Northern blotting using four Icsbp cDNA probes, designated as 537, 841, 909, and 47-1270. Probes 537, 841, and 47-1270 detected two mRNAs of
3.0 kb and 1.7 kb, respectively, whereas probe 909 detected only the 3.0 kb transcript. The tumors with proviral insertions at Icsbp are marked in bold andwith a triangle.
Ethidium staining of 28S and 18S ribosomal RNA served as loading controls. The lower right panel depicts the structure of the cDNA probes in relation to the exon–
intron organization of the Icsbp locus. A potential alternative poly(A) signal (ATTAAA) at position 1491–1496 of M32489 is indicated.
Fig. 5. Chimeric transcripts generated by proviral insertions into exon 9 of Icsbp. (A and B) Northern blot hybridization of RNAs from Akv wt (A) and Akv1-99 mEa/s
(B) induced tumors with probes 537, 847, and 909. Probes 537 and 841 detected a 2.1 kb chimeric transcript in tumor 01-241 (A; top), and a 1.8 kb chimeric transcript
in tumor 01-1080 (B; top). DNA of tumors 01-241 and 01-1080 contained a proviral integration in the 3´UTR sequence in exon 9 of Icsbp (A; bottom) and in the
coding sequence in exon 9 of Icsbp (B; bottom), respectively. Black or white rectangles represent coding/noncoding exons of Icsbp, while grey rectangles represent
provirus sequences in the recombinant transcripts. The flags denote insertion sites and the horizontal arrows the primers used for PCR analysis. (C) Total RNA
extracted from tumors 01-1080 and 01-241 was reverse-transcribed using an oligo(dT)-primer. Products of subsequent RT-PCR reactions using the primer pairs shown
in lower panels of A and B were analyzed by agarose gel electrophoresis.
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Fig. 6. Chimeric transcripts generated by proviral insertions into intron 2 and intron 5 of Icsbp. (A and B) Northern blot hybridization with probe 537 of RNA from
tumors 01-742 (A; top) and 01-282 (B; top). Indicated are the 3.0 kb long transcript and the 1.7 kb short transcript. Recombinant transcripts detected in tumors 01-742
and 01-282 are illustrated in panels A and B (bottom). Black or white rectangles represent coding/noncoding exons of Icsbp, while grey rectangles represent provirus
sequences in the recombinant transcripts. The flags denote insertion sites and the horizontal arrows the primers used for PCR analysis. (C) Total RNA from tumors 01-
742 and 01-282 was reverse-transcribed using an oligo(dT)-primer, and the PCR products made using the primers depicted in panels A and B were analyzed by agarose
gel electrophoresis. The bands were sequenced to reveal the recombinant RNA structures depicted in panels A and B.
313S.L. Ma et al. / Virology 352 (2006) 306–318fragments of 410 bp for tumor 01-742 and 2472 bp for tumor
01-282 (Fig. 6C). Sequence determination revealed that the
chimeric transcript of tumor 01-742 contained Icsbp exons 1–5
which by usage of a cryptic splice splice-acceptor site in intron
5 were fused together with a small part (10 nucleotides) of
intron 5 connected to the viral U3 region, and making use of the
poly(A) signal in the 5′LTR of the provirus. Moreover, the
Northern blotting hybridization (Fig. 6A) revealed an
additional, yet weakly expressed transcript of about 0.5 kb,
which probably corresponded to this transcript. In case of
tumor sample 01-282, sequence determination of the PCR
fragments revealed that the chimeric transcript was composed
of Icsbp exons 1 and 2 spliced together with the 3′end of the
integrated provirus. The splice-donor (SD) site of Icsbp exons
2 had been used together with the canonical splice-acceptor
(SA) site in the provirus (the SA normally used to produce
the spliced envelope transcript), thereby producing a com-
posite transcript containing Icsbp exons 1–2 and an MLV
envelope gene. However, the Northern blot hybridization
(Fig. 6B) did not show specific bands corresponding to this
transcript, either because it is co-migrating with the 3.0 kb
band or because the copy number is too low for detection,
considering that its only match with probe 537 is the
sequence of exon 2.
Altogether, these analyses establish that in all cases where a
provirus had integrated in a co-trancriptional orientation within
the Icsbp gene, chimeric transcripts were produced; however,
only when the integration took place within an exon was a
substantial expression level observed. The significance of these
findings is not clear in terms of qualitative or quantitative
changes in ICSBP protein. However, they positively contribute
to the notion that the Icsbp is indeed the gene, which has beenaffected by the integrated proviruses, and which in a still
unknown way is involved in B-cell lymphomagenesis.
The ICSBP protein level in tumors is not generally affected by
the proviral Icsbp insertions
Since we found that the proviral Icsbp insertions in general
did not significantly affect Icsbp RNA expression, we wanted to
see if this was reflected in the ICSBP protein level in the tumor
samples. Western blot analyses were performed on tumor
samples of three series (comprising 3 tumors with and 12
tumors without insertion at the Icsbp locus) (Fig. 7), which
resulted in the same overall picture as the Northern-blot
analyses: in all tumor samples, a similar protein level was
observed, which was not affected by the presence of an Icsbp
provirus insertion. Only in the two cases where the insertions
were found in Icsbp exon 9, was a slightly increased protein
level detected, which may mirror the strongly expressed
alternative transcripts observed in these tumors. The site of
insertion in tumor 01-1080 predicts the formation of an ICSBP
protein devoid of the last 5 amino acids, which may influence its
detection by the antibody.
Discussion
Mouse models of retroviral insertional mutagenesis have
become an essential cancer-gene discovery tool in the era of
post genome-sequence completion. Making use of such a model
of MLV-induced lymphomas in NMRI mice, in the present
study we have identified 14 insertions within the Icsbp locus by
a high-throughput sequencing approach—in which a total of
approximately 3000 proviral integration sites were isolated.
Fig. 7. Western blot analysis of ICSBP in tumors. Tumor tissues were homogenized and 10 μg of protein was separated by SDS-polyacrylamide gel electrophoresis.
After immunoblotting, protein levels were chemoluminescently detected. Beta-actin staining was used as a loading control. (A) Analysis of Akv1-99mEa/s-induced
tumors; tumor 01-994 has a proviral insertion into intron 2 of Icsbp. (B) Analysis of Akv1-99 wt (lanes 1–4) and Akv1-99 mEa/s (lanes 5–8) induced tumors; tumors
01-241 and 01-1080 have proviral insertions in exon 9 outside and within the coding sequences, respectively (see Fig. 1). The right panel shows ICSBP/Beta-actin
ratios determined by PhosphorImager analysis.
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(RTCGD; http://RTCGD.ncifcrf.gov) Akagi et al., 2004) for
previously identified proviral integrations in this locus revealed
no such hits; thus Icsbp denotes a novel common integration site
(CIS) as has been defined by Suzuki et al. (2002).
Remarkably, all but one of the integrations were found in
tissues, which by Southern blot and histopathological analyses
could be classified as being of B-cell origin despite the fact that
about half of isolated proviral tags were derived from tumors of
T-cell origin. This strongly implies a B-cell-restricted role of the
Icsbp locus in the development of lymphoid malignancies.
However, expression analyses of Icsbp in tumor tissues did not
reveal any common pattern of changes in either RNA or protein
levels when compared to equivalent tumor tissues with no Icsbp
provirus insertions. Thus, it seems that the consequence of the
integrations is not merely a matter of activation or suppression
of ICSBP expression, which in turn would have led to an
oncogenic development. On the other hand, the expression
analyses were performed on end-stage tumor tissues, so it
cannot be ruled out that a disturbance of expression might have
taken place earlier on in the progression of the tumors. Such an
early disturbance might somehow have put a selection pressure
to the cells that eventually might have expanded and
transformed into malignant clones. Nevertheless, the stable
Icsbp expression that we observed in MLV-induced lymphomas
is in sharp contrast to what has been reported for the myeloid
cancers in which Icsbp seems to hold a tumor suppressoractivity as demonstrated by ICSBP down regulation in cancer
tissues (Hao and Ren, 2000; Schmidt et al., 2004). Hence, this
supports a view that the cancer-related function of ICSBP
depends very much on the cell-type context.
Alternatively, one may argue that the reason why no
expression alterations can be detected in the MLV-induced
lymphomas could be that it is not at all the Icsbp gene itself
which is affected by the integrated proviruses. It is well-known
that integrated proviruses may influence genes that are located
several hundreds kilobase away from the insertion sites (Lazo et
al., 1990). Accordingly, the actual target gene may be one of the
neighboring genes (depicted in Fig. 1). However, this seems not
to be a plausible explanation for several reasons. First and
foremost, the extremely distinct pattern of clustering around and
within the Icsbp gene quite convincingly points to Icsbp as the
target gene. Second, the chimeric transcripts that were produced
and heavily expressed when the integrations were located in
Icsbp exon sequences further add support to this gene being the
central one, and at last, our expression analyses of the two most
closely situated genes, Cox4i1 and Cox4nb (data not shown),
did not reveal changes in expression pattern. Likewise, a search
for mouse microRNAs within the 100 kb window at Icsbp at
http://www.sanger.ac.uk/Software/Rfam/mirna/ did not reveal
any candidates. Hence, the most obvious deduction is that Icsbp
is indeed the target gene.
Currently, more than 2200 RISs and almost 400 CISs are
contained in the RTCG database. Some of the CISs appear to be
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play a role in a wider range of cell types. Moreover, the
frequency with which the individual CISs are targeted depends
very much on the model system, i.e. mouse strain and type of
retrovirus. For example, both Moloney and SL3-3 MLVs induce
T-cell lymphomas, but their mutual relative strengths vary with
the host-genetic background, and so does the pattern of
preferred target genes (Blyth et al., 2001; Kim et al., 2003;
Mikkers et al., 2002a, 2002b; Nielsen et al., 2005). This fact
may contribute to a clarification of the quite unexpected finding
that Icsbp could not be found in the RTCGD, not even as an
RIS, although about half of the CISs in the database can be
correlated with B-cell malignancies. The majority of the B-cell-
related CISs do in fact originate from Akv or Akv-related
proviral integrations, but in contrast to the present study, tumor
induction has in all cases been caused by expression of an
endogenous MLV, yet in various mouse genetic backgrounds
such as AKR, AKXD, NFS.V+, CWD, SJL/J, and SL/Kh mice
(Gilbert et al., 1993; Hartley et al., 2000; Mucenski et al., 1986;
Yamada et al., 1994). Thus, a straightforward explanation of the
lack of Icsbp hits in RTCGD would be that the genetic
composition in the NMRI strain somehow makes these mice
more prone to tumor induction by Akv proviral insertions in the
Icsbp locus.
Since all known B-cell-related CISs are correlated with
endogenous MLV tumor induction, an alternative explanation
could be suggested. An exogenous MLV might trigger an early
ICSBP-affected modulation of an immune response, which at
the same time may play a role in the initiation and/or
progression of B-cell tumor development. Infection within the
first 2 to 3 days after birth is critical for lymphomagenesis by
exogenous MLVs. Although the establishment of some level
of immunological tolerance by such early infection is
important to allow progression of viral replication, the
mechanisms are poorly understood, and it is conceivable that
the virus may elicit innate and adaptive immune response
signaling (Sarzotti et al., 1996). MLVs and other retroviruses
have been found to interact with Toll-like receptors, which are
important for an early innate host response to viral infections
(Rassa et al., 2002). Likewise, the transmembrane protein of
MLV harbors an immunosuppressive peptide motif with an
influence on immune signaling, although the exact signaling
pathways are poorly defined (Haraguchi et al., 1995). An early
innate immune response to exogenous MLV might skew a
delicate balance of cytokines and push the cells to an increased
proliferation stage. The constitutive expression of Icsbp
modulates NF-κB stimulation through toll-like receptor
(TLR) signaling, which could lead to tumor survival and
inhibition of apoptosis (Bernal et al., 2001; Cahir-McFarland
et al., 2000; Darnell, 2002). ICSBP might also be involved in
these processes by regulating IL-12 production. In these
settings, cells with deregulated expression of Icsbp as a result
of proviral insertions at the locus may be favored.
We have previously observed plasma cell proliferation and
plasmacytoma induction following infection of newborn mice
of the inbred NMRI strain with the Akv1-99 virus and proposed
that this disease model may have an antigen-stimulatorycomponent (Sorensen et al., 2005). The inbred NMRI strain
appears particularly prone to lymphoma induction by exoge-
nous Akv and related viruses (Sorensen et al., 2005), possibly
reflecting an influence of the genetic composition of this mouse
strain on the regulation of innate or adaptive immune responses.
An expanded cell population would gain an increased
probability for additional insertional mutagenesis events,
which could serve to further stimulate growth in an autocrine
or paracrine manner or represent a genuine transformation
event. Such processes could lead to the outgrowth of polyclonal
or oligo-/monoclonal tumors of malignant or chronically
stimulated cells.
The model presented here with the frequent targeting of
the Icsbp locus preferentially in B-cell lymphomas induced
by an exogenous MLV, and the steady RNA/protein
expression in tumor tissues may add an interesting
experimental approach for future investigations of links
between an innate or adaptive immune response and the
development of B-cell lymphomas.
Materials and methods
Origin of lymphomas and MLV variants
Mouse lymphomas induced by wt and mutants of Akv and
SL3-3 MLVs (from a total of 1203 mice) were available from
our earlier and unpublished work (Ethelberg et al., 1997,
1999; Hallberg et al., 1991; Lovmand et al., 1998, 1990; Lund
et al., 1999; Sorensen et al., 1996, 2000, 2005). In short,
newborn inbred NMRI mice were injected with approximately
105 infectious virus particles, and the mice were sacrificed
when they showed signs of illness (Schmidt et al., 1988).
Spleen, thymus, and lymph nodes were dissected and
measured, and samples were immediately frozen at −80 °C.
Tumor development was diagnosed on the basis of grossly
enlarged lymphatic organs (the defined sizes have been
described previously; Schmidt et al., 1984). The tumors
found positive for insertions at the Icsbp locus were induced
by the following viruses: Akv wild type (Akv wt), an Akv
primer binding site (PBS) mutant, an Akv gag splice mutant,
five different Akv U3 enhancer mutants (Akv1-99 NF1 dm,
Akv1-99 wt, Akv1-99 mRunx + mEgre, Akv1-99
mEgre + mEa/s, and Akv1-99 mEa/s), and finally, one
attenuated SL3-3 variant (SL3-3 Runx dm) (description of
virus structures have been described previously/will be
described elsewhere; Ethelberg et al., 1997, 1999; Hallberg
et al., 1991; Lovmand et al., 1998, 1990; Lund et al., 1999;
Olsen et al., 1990; Sorensen et al., 2005).
Provirus tagging and statistical analyses
1203 mouse tumors were screened for proviral insertion
sites at Sagres Discovery, Inc. (California, USA) using high-
throughput provirus tagging procedures (Rasmussen et al.,
2005). Assuming a random distribution of 3000 retroviral
integrations into the mouse genome (3 × 109 bp), the
expected frequency of tagging a site within the Icsbp locus
316 S.L. Ma et al. / Virology 352 (2006) 306–318(1 × 105 bp) would be 0.1. According to the Poisson
distribution
P X ¼ vð Þ ¼ l
vel
v!
where μ is the frequency of random-tagged sites in the
mouse genome, and χ is the frequency of observed tagged
sites in the 100 kb Icsbp locus.Histopathological examination
Hematoxylin and eosin (H&E) sections from formalin- or
paraformaldehyde-fixed and paraffin-embedded tissue (lymph
nodes, thymus spleen, and liver) were revised for all tumors
found to be positive for insertion at the Icsbp locus. In addition,
immunohistochemical stains were carried out for these 14 cases.
Tumors were classified according to the Bethesda proposals for
classification of lymphoid neoplasms in mice (Morse et al.,
2002). Immunohistochemistry was performed on an automated
immunostainer (Ventana Medical System, Inc.; AZ, USA),
according to the protocol provided by the company with slight
modifications. After deparaffinization and rehydration, the
slides were placed in a microwave pressure cooker in 0.01 M
citrate buffer (pH 6.0), containing 0.1% Tween 20 and heated in
a microwave oven at maximum power for 30 min. After cooling
in Tris-buffered saline, the sections were incubated with 3%
goat or rabbit serum for 20 min. The antibody panel used
included polyclonal anti-CD3, monoclonal anti-CD79acy, and
monoclonal anti-TdT (Dako, Germany); polyclonal anti-Bcl6
(Santa Cruz, CA, USA); monoclonal rat anti-CD138 and anti-
B220/CD45R (BD Bioscience, NJ, USA); and monoclonal
rabbit anti-ki67 (DCS, Germany). Appropriate positive controls
were used to confirm the adequacy of the staining.
Southern blotting analyses
Genomic DNA was extracted from frozen tissues, digested
with HindIII or EcoRI, electrophoretically separated on a 0.8%
agarose gel, blotted onto a nylon membrane (Amersham
Biosciences), and hybridized with the following 32P random
priming labeled probes: T-cell receptor (TCR)-β chain joining
region 1 (TCR-J1) and region 2 (TCR-J2) probes, immuno-
globulin kappa light-chain (Igκ) probe, immunoglobulin heavy-
chain (IgH) probe, and an ecotropic-specific envelope probe (all
probes and hybridization procedures have been described earlier
by Lovmand et al., 1998).
Northern blotting analyses
Total RNA was extracted from frozen tumor tissues using
TRIzol reagent according to the manufacturer's instructions
(Invitrogen Life Technologies). For Northern blotting, 20 μg of
total RNAwas electrophoretically separated on a denaturing 1%
agarose gel (1× MOPS, 6.7% formaldehyde) and transferred to
a positively charged nylon membrane (Amersham Biosciences)
by capillary action, fixed, prehybridized, and hybridized with32P random priming labeled probes corresponding to Icsbp
cDNA fragments, named probe 537 (covers nts 47-558 of
GenBank accession number M32489), probe 841 (covers nts
453-1293 of M32489), probe 909 (covers nts 1462-2370 of
M32489), and probe 47-1270 (covers nts 47-1270 of M32489).
Hybridization and washing procedures have previously been
described (Sorensen et al., 2000). The integrity and concentra-
tion of the RNAwere confirmed/estimated by visual inspection
of ethidium bromide-stained 18S and 28S rRNAs.
RT-PCR and sequencing
For RT-PCR, 600 ng total RNAwas used to make first-strand
cDNA (Amersham Biosciences) with oligo-dT primer, followed
by PCR amplification using a MLV ecotropic-specific down-
stream primer and Icsbp-specific upstream primers. The
downstream ecotropic MLV primer was: 2620; 5′-GAATTC-
GATATCGATCCCCGGTCATCTGGG-3′(Lovmand et al.,
1998; Sorensen et al., 1993); Icsbp-specific primers were: 47;
5′-GCTGCGGCAGTGGCTGATCGAACAGATCG-3′, and
453; 5′-GAGCTGATCAAGGAACCTTCTGTG-3′. PCR pro-
ducts were purified with GFX, and sequences were determined
by the use of ABI 7300 Biosystems.
Western blotting analyses
Equal amounts of proteins (10 μg) were separated by (SDS-
PAGE), and electro-blotted onto polyvinylidene fluoride
(PVDF) membranes (Boehringer Mannheim). The membrane
was blocked in TBS (20 mM Tris, 137 mM NaCl, pH 7.6)
(TBS) containing 3% BSA. Membranes were then incubated for
1 h with 1:6000 dilution of affinity-purified goat polyclonal
anti-mouse ICSBP antibody directed against the C-terminal 17
amino acid-peptide of the protein (Sc-6058) (Santa Cruz
Biotechnology, Inc.) in TBS containing 0.05% Tween-20
(TBST) and 3% BSA. After five washes with wash buffer
(TBS, 0.01% Tween-20, 0.1% BSA), membranes were
incubated with 1:2000 dilutions of horseradish peroxidase
(HRP)-linked secondary antibody of rabbit anti-goat immuno-
globulins/HRP (DAKO A/S, Denmark) in PBST containing 3%
BSA. Then the membranes were washed in wash buffer, and
Western detection of ICSBP was conducted using the ECL Plus
Western Blotting Detection System (Amersham Biosciences).
Blots were exposed to Konica Medical film (Konica Minolta
Medical and Graphic Inc.). After stripping, membranes were
reincubated with 1:6000 dilutions of goat polyclonal anti-
human β-actin antibody (I-19) (Santa Cruz Biotechnology, Inc.)
for internal control of total protein loading.
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